These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15548526)

  • 101. Structural perspectives on chemokine receptors.
    Kayastha K; Zhou Y; Brünle S
    Biochem Soc Trans; 2024 Jun; 52(3):1011-1024. PubMed ID: 38856028
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Chemokine receptor CCR1: new target for asthma therapy.
    Barnes PJ
    Trends Pharmacol Sci; 2022 Jul; 43(7):539-541. PubMed ID: 35246315
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.
    Gilchrist A; Echeverria SL
    Front Endocrinol (Lausanne); 2022; 13():846310. PubMed ID: 35399952
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Inflammatory Role of CCR1 in the Central Nervous System.
    Tian Q; Yan Z; Guo Y; Chen Z; Li M
    Neuroimmunomodulation; 2024; 31(1):173-182. PubMed ID: 39116843
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Fluorophore-Labeled Pyrrolones Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR1.
    Toy L; Huber ME; Lee M; Bartolomé AA; Ortiz Zacarías NV; Nasser S; Scholl S; Zlotos DP; Mandour YM; Heitman LH; Szpakowska M; Chevigné A; Schiedel M
    ACS Pharmacol Transl Sci; 2024 Jul; 7(7):2080-2092. PubMed ID: 39022357
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation.
    Matthews EE; Thévenin D; Rogers JM; Gotow L; Lira PD; Reiter LA; Brissette WH; Engelman DM
    FASEB J; 2011 Jul; 25(7):2234-44. PubMed ID: 21402716
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Mechanisms regulating chemokine receptor activity.
    Bennett LD; Fox JM; Signoret N
    Immunology; 2011 Nov; 134(3):246-56. PubMed ID: 21977995
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.
    Ukani R; Lewis TC; Day TP; Wu W; Malladi SS; Warshakoon HJ; David SA
    Bioorg Med Chem Lett; 2012 Jan; 22(1):293-5. PubMed ID: 22104149
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Potent and selective CC chemokine receptor 1 antagonists labeled with carbon-13, carbon-14, and tritium.
    Latli B; Hrapchak M; Cheveliakov M; Reeves JT; Marsini M; Busacca CA; Senanayake CH
    J Labelled Comp Radiopharm; 2018 May; ():. PubMed ID: 29766547
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1.
    Shao Z; Shen Q; Yao B; Mao C; Chen LN; Zhang H; Shen DD; Zhang C; Li W; Du X; Li F; Ma H; Chen ZH; Xu HE; Ying S; Zhang Y; Shen H
    Nat Chem Biol; 2022 Mar; 18(3):264-271. PubMed ID: 34949837
    [TBL] [Abstract][Full Text] [Related]  

  • 111. CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration.
    Fox JM; Kausar F; Day A; Osborne M; Hussain K; Mueller A; Lin J; Tsuchiya T; Kanegasaki S; Pease JE
    Sci Rep; 2018 Jun; 8(1):9466. PubMed ID: 29930254
    [TBL] [Abstract][Full Text] [Related]  

  • 112. What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?
    Kufareva I; Gustavsson M; Zheng Y; Stephens BS; Handel TM
    Annu Rev Biophys; 2017 May; 46():175-198. PubMed ID: 28532213
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.
    Brenner AK; Nepstad I; Bruserud Ø
    Front Immunol; 2017; 8():106. PubMed ID: 28232835
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Structural Analysis of Chemokine Receptor-Ligand Interactions.
    Arimont M; Sun SL; Leurs R; Smit M; de Esch IJP; de Graaf C
    J Med Chem; 2017 Jun; 60(12):4735-4779. PubMed ID: 28165741
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5.
    Corbisier J; Huszagh A; Galés C; Parmentier M; Springael JY
    J Biol Chem; 2017 Jan; 292(2):575-584. PubMed ID: 27895119
    [TBL] [Abstract][Full Text] [Related]  

  • 116. CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779.
    Nedjai B; Viney JM; Li H; Hull C; Anderson CA; Horie T; Horuk R; Vaidehi N; Pease JE
    Br J Pharmacol; 2015 Apr; 172(7):1822-33. PubMed ID: 25425280
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.
    Viney JM; Andrew DP; Phillips RM; Meiser A; Patel P; Lennartz-Walker M; Cousins DJ; Barton NP; Hall DA; Pease JE
    J Immunol; 2014 Apr; 192(7):3419-27. PubMed ID: 24563252
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Structure-based network analysis of an evolved G protein-coupled receptor homodimer interface.
    Nichols SE; Hernández CX; Wang Y; McCammon JA
    Protein Sci; 2013 Jun; 22(6):745-54. PubMed ID: 23553730
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.
    Rummel PC; Arfelt KN; Baumann L; Jenkins TJ; Thiele S; Lüttichau HR; Johnsen A; Pease J; Ghosh S; Kolbeck R; Rosenkilde MM
    Br J Pharmacol; 2012 Nov; 167(6):1206-17. PubMed ID: 22708643
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2.
    Jensen PC; Thiele S; Steen A; Elder A; Kolbeck R; Ghosh S; Frimurer TM; Rosenkilde MM
    Br J Pharmacol; 2012 May; 166(1):258-75. PubMed ID: 22050085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.